Seer, Inc. Class A Common Stock (SEER)
Seer, Inc. Class A (SEER) is a biotechnology company focused on developing advanced proteomics technologies to enable detailed analysis of proteins in biological samples. Its platform aims to facilitate breakthroughs in drug discovery, diagnostics, and research by providing high-throughput, precise, and scalable protein measurement solutions.
Company News
Seer showcased how proteomics complements genomics in precision medicine research at the American Society of Human Genetics 2025 conference, presenting multiple scientific studies demonstrating the potential of their Proteograph Product Suite to uncover novel biomarkers and enhance disease understanding.
Seer, a life sciences technology firm, reported Q2 2025 revenue of $4.1 million, exceeding analyst expectations by 9.3% and representing a 32% year-over-year increase. Despite revenue growth, the company remains unprofitable with continued operating losses.
Seer (SEER) delivered earnings and revenue surprises of -3.23% and 13.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Nasdaq 100 closed higher by around 1% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for ma...